Skip to main content


Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: The role of neoantigen in immune checkpoint blockade therapy

Fig. 2

The number of mutant gene across 29 types of tumor. Average mutant gene number is calculated based on TCGA datasets ( ACC adrenocortical cancer, BLCA bladder cancer, CESC cervical cancer, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, DLBC lymphoid neoplasm diffuse large B-cell lymphoma, ESCA esophageal carcinoma, GBM glioblastoma multiforme, HNSC head & neck squamous cell carcinoma, KICH kidney chromophobe cancer, KIRC Kidney renal clear cell carcinoma, KIRP kidney papillary cell carcinoma, LAML acute myeloid leukemia, LIHC hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PRAD prostate adenocarcinoma, READ rectal cancer, SARC sarcoma, SKCM melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumor, THCA thyroid cancer, THYM thymoma, UCEC endometrioid cancer, UCS uterine carcinosarcoma

Back to article page